Insights on the Naloxone Global Market to 2030 - Increasing Prevalence of Opioid Overdoses Remains as The Most Impactful Driver
30 janv. 2023 09h33 HE
|
Research and Markets
Dublin, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The "Naloxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to...
Heart to Heart CPR Raises Awareness of Ontario's NEW Workplace Naloxone Requirements Effective June 1, 2023
10 janv. 2023 08h08 HE
|
Heart to Heart First Aid CPR Services Inc
TORONTO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- As of June 1, 2023, the Occupational Health and Safety Act (OHSA) will require workplaces to have a naloxone kit if an employer becomes aware, or ought...
Fentanyl Drives Fatal Overdoses to Over 107,000 Annually in the U.S. - Healthcare Providers' Effort to Fight Back
24 août 2022 09h00 HE
|
Cordant Health Solutions
PORTLAND, Ore., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cordant Health Solutions®, a leader in providing innovative tools for addiction treatment programs, is partnering with addiction treatment providers...
US WorldMeds Launches ZIMHIDirect.com
05 juil. 2022 11h32 HE
|
US WorldMeds
LOUISVILLE, Ky., July 05, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds) announces ZIMHI™ (naloxone HCL Injection) 5mg/0.5mL is now available for ordering by public interest groups through the...
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
01 juin 2022 08h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Global Global Suboxone Market Analysis/Forecast Report 2022-2030: Increasing Product Launches is Expected to Drive Growth
24 mai 2022 06h49 HE
|
Research and Markets
Dublin, May 24, 2022 (GLOBE NEWSWIRE) -- The "Global Suboxone Market by Type, Formulation, Distribution Channel, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has...
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
01 déc. 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...
Adamis Receives FDA Approval for ZIMHI
18 oct. 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone...
Adamis Provides Update on ZIMHI™
09 juin 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s...
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
17 mai 2021 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be...